These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21552904)

  • 1. Antibody-induced inhibition of growth of egfr overexpressing tumors occurs in the absence of receptor down-regulation.
    Modjtahedi H; Dean C
    Int J Oncol; 1995 Oct; 7(4):783-8. PubMed ID: 21552904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies directed against the EGF receptor show differential bindings of amphiregulin and EGF to the EGF receptor.
    Modjtahedi H; Cohen B; Dean C
    Int J Oncol; 1997 Feb; 10(2):339-47. PubMed ID: 21533382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
    Modjtahedi H; Komurasaki T; Toyoda H; Dean C
    Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H; Affleck K; Stubberfield C; Dean C
    Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies to the EGF receptor act as betacellulin antagonists.
    Modjtahedi H; Dean C
    Biochem Biophys Res Commun; 1996 Apr; 221(3):625-30. PubMed ID: 8630011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
    Modjtahedi H; Styles JM; Dean CJ
    Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
    Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
    Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes.
    Zyzak LL; MacDonald LM; Batova A; Forand R; Creek KE; Pirisi L
    Cell Growth Differ; 1994 May; 5(5):537-47. PubMed ID: 8049160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
    Gu J; Chen L; Shatos MA; Rios JD; Gulati A; Hodges RR; Dartt DA
    Exp Eye Res; 2008 Feb; 86(2):322-34. PubMed ID: 18155194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
    Modjtahedi H; Eccles S; Box G; Styles J; Dean C
    Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction.
    Reins HA; Steinhilber G; Freiberg B; Anderer FA
    J Cell Biochem; 1993 Feb; 51(2):236-48. PubMed ID: 8382707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.
    Fattah OM; Cloutier SM; Kündig C; Felber LM; Gygi CM; Jichlinski P; Leisinger HJ; Gauthier ER; Mach JP; Deperthes D
    Int J Cancer; 2006 Nov; 119(10):2455-63. PubMed ID: 16858684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of cytotoxic effect of epidermal growth factor (EGF) on EGF receptor overexpressing cells is associated with attenuation of EGF receptor tyrosine kinase activity.
    Gardner DP; Shimizu N
    J Cell Physiol; 1994 Feb; 158(2):245-55. PubMed ID: 8106561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
    Modjtahedi H; Hickish T; Nicolson M; Moore J; Styles J; Eccles S; Jackson E; Salter J; Sloane J; Spencer L; Priest K; Smith I; Dean C; Gore M
    Br J Cancer; 1996 Jan; 73(2):228-35. PubMed ID: 8546911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone alters epidermal growth factor receptor binding affinity via activation of extracellular signal-regulated kinases in 3T3-F442A cells.
    Huang Y; Chang Y; Wang X; Jiang J; Frank SJ
    Endocrinology; 2004 Jul; 145(7):3297-306. PubMed ID: 15070853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.